GERMANTOWN

Monkee's announces Germantown Grand Opening

Retrieved on: 
Thursday, February 15, 2024
Love, Woman, Suite, Small business, Personality, ALSAC, The Sundays, Golden Joystick Awards, Shoe, Fashion design

GERMANTOWN, Tenn., Feb. 14, 2024 /PRNewswire/ -- Monkee's Franchising is excited to announce the Grand Opening of Monkee's of Germantown opening Friday, February 16, 2024.

Key Points: 
  • GERMANTOWN, Tenn., Feb. 14, 2024 /PRNewswire/ -- Monkee's Franchising is excited to announce the Grand Opening of Monkee's of Germantown opening Friday, February 16, 2024.
  • With locations in 12 different states, Monkee's of Germantown will be Monkee's 52nd open store and the fourth store in Tennessee.
  • Monkee's of Germantown will have trunk shows with Marie Oliver and Allison Avery during the grand opening weekend, along with a giveaway of a $250 gift card and several pairs of earrings.
  • The store is located at 1730 S. Germantown Rd, Suite 112 and will be open Monday through Saturday from 10 a.m. to 6 p.m.
    For more information about the Grand Opening of Monkee's of Germantown or Monkee's Franchising, visit shopmonkees.com and follow @monkeesofgermantown on Instagram.

Agent PHL Brokers ±19,000 SF Development Site in Philadelphia for $2,085,000

Retrieved on: 
Wednesday, October 25, 2023
Sale, 30th Street Station, PHL, Chestnut Hill West Line, Restaurant, Walking, Client, Agent, Septa, Germantown Pike, Chestnut Hill, Tunnel, Procurement, Amtrak

PHILADELPHIA, Oct. 25, 2023 /PRNewswire/ -- On behalf of The Buyer, Agent PHL has formally announced the sale and settlement of 6915 Germantown Avenue in Philadelphia, Pennsylvania.

Key Points: 
  • PHILADELPHIA, Oct. 25, 2023 /PRNewswire/ -- On behalf of The Buyer, Agent PHL has formally announced the sale and settlement of 6915 Germantown Avenue in Philadelphia, Pennsylvania.
  • The West Mount Airy site will provide a brand new apartment building in a thriving Northwest Philly marketplace experiencing surging tenant demand.
  • The sale was brokered by Ryan McManus, principal of Agent PHL— in collaboration with Kevin Cybularz of Twyn Real Estate, LLC.
  • The ±19,000 SF Property bound by Gorgas Lane to the east and Sedgwick Street to the west is located just ten (10) miles from Amtrak's 30th Street Station in downtown Philadelphia.

Quarterra Multifamily Announces Start of Leasing at Towne Nashville Apartments

Retrieved on: 
Thursday, June 29, 2023
Music Row, Lennar, Music, EV, First Horizon Park, Culture, Tennessee State University, Daughter, Bicentennial Capitol Mall State Park, Nashville Sounds, Avenue B (Manhattan), Interstate 24, Microsoft, Wi-Fi, History, I-65, ChargePoint, Tanning, Slim, Amazon, Southeast Division, Restaurant, HCA, Garfield Street Historic District, Elizabeth Park, Common, Hotel, Mirror

NASHVILLE, Tenn., June 29, 2023 /PRNewswire/ -- Quarterra Multifamily, a subsidiary of Lennar Corporation and a vertically integrated multifamily apartment builder, developer, and property manager, today announced the start of leasing at Towne Nashville, a 329-home mid-rise community in Nashville's vibrant Germantown neighborhood.

Key Points: 
  • NASHVILLE, Tenn., June 29, 2023 /PRNewswire/ -- Quarterra Multifamily , a subsidiary of Lennar Corporation and a vertically integrated multifamily apartment builder, developer, and property manager, today announced the start of leasing at Towne Nashville , a 329-home mid-rise community in Nashville's vibrant Germantown neighborhood.
  • Towne harnesses the neighborhood vibe to offer a connected, inclusive and socially-driven living experience.
  • The area is also home to the Nashville Farmers Market, with its eclectic global dining options and seasonal produce vendors.
  • Towne is Quarterra's third development in Nashville and second managed property, joining The Morris – a high-rise community on Music Row.

TeraImmune Extends CRADA for Development of Treg Expansion for Clinical Use

Retrieved on: 
Wednesday, January 4, 2023
National Institute of Allergy and Infectious Diseases, Clinical trial, Multiple sclerosis, Research, CRADA, Infection, Development, NIAID, Degenerative disease, NIH, Atopic dermatitis, Doctor of Philosophy, Helios, Cooperative research and development agreement, Vaccine, Regulatory T cell

The CRADA is entitled “Developing the process of human regulatory T cells for clinical use.”

Key Points: 
  • The CRADA is entitled “Developing the process of human regulatory T cells for clinical use.”
    Under the agreement, TeraImmune continues to develop cGMP-compliant manufacturing protocol for its lead candidate, TI-168, and clinical laboratory manuals designed to provide relevant tactical support for the upcoming clinical trial.
  • NIAID provides scientific advice on the therapeutic use of Tregs and on establishing cGMP-grade Treg manufacturing processes, as well as assists in the development of standard operating procedures for the preclinical and clinical stage development of cGMP-grade Treg cell therapy.
  • TeraImmune licensed one of its key technologies for a stable expansion of functional regulatory T cells from NIAID.
  • “We are excited to continue our cooperative research with Dr. Shevach,” said Yong Chan Kim, PhD, Chief Executive Officer of TeraImmune.

TeraImmune Presented Research on TREGable™ Technology at HCA Asia 2022

Retrieved on: 
Friday, November 18, 2022
Degenerative disease, Doctor of Philosophy, Teff, DNA, Biotechnology, TFS, Patient, Atopic dermatitis, B cell, MD, ATAC, Skin, Whole blood, Manuscript, TCR, Immunology, TF, Pharmaceutical industry, Vaccine, Regulatory T cell

GERMANTOWN, Md., Nov. 18, 2022 (GLOBE NEWSWIRE) -- TeraImmune, Inc., a biotechnology company focused on the discovery and development of novel Treg-based cell therapies for autoimmune diseases, announced today that it presented data on its TREGable technology at the Human Cell Atlas Asia (HCA Asia) 2022 Meeting that took place on November 3 4 in Bangkok, Thailand.

Key Points: 
  • GERMANTOWN, Md., Nov. 18, 2022 (GLOBE NEWSWIRE) -- TeraImmune, Inc., a biotechnology company focused on the discovery and development of novel Treg-based cell therapies for autoimmune diseases, announced today that it presented data on its TREGable technology at the Human Cell Atlas Asia (HCA Asia) 2022 Meeting that took place on November 3 4 in Bangkok, Thailand.
  • Through this company sponsored study, the researchers characterized, co-cultured and expanded Treg with 25-mer DNA oligonucleotide (named TREGable technology).
  • We continue to be excited to share our highly anticipated Treg expansion technology with the world, said Yong Chan Kim, PhD, Chief Executive Officer of TeraImmune.
  • We are thrilled to be able to share our TREGable technology and look forward to preparing a manuscript for publication in a scientific journal.

Taconic Biosciences Launches First and Only Super Immunodeficient Mouse Models Lacking Residual Murine Fc Gamma Receptors, for Improved Antibody Therapy Assessment

Retrieved on: 
Monday, October 24, 2022
NOG, Therapy, Neoplasm, Autoimmune disease, Animal, Tissue, Taconic Biosciences, Immune system, Drug discovery, FC, GLOBE, Monoclonal antibody, Solution, Fc receptor, Vaccine, Taconic

RENSSELAER, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has launched the FcResolv NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors (FcRs) known to confound results in antibody-based therapy studies.

Key Points: 
  • RENSSELAER, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has launched the FcResolv NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors (FcRs) known to confound results in antibody-based therapy studies.
  • Murine FcRs can cause false positives or false negatives, leading to incorrect conclusions and derail drug discovery.
  • Taconics FcResolv NOG portfolio enables researchers to evaluate drug candidates like these on their own merits, free of interference from residual murine Fc gamma receptor activity.
  • The FcResolv NOG model portfolio is based on the super immunodeficient CIEA NOG mouse.

TeraImmune Receives FDA IND Clearance to Initiate Phase 1/2a Clinical Trial of TI-168 for Treatment of Hemophilia A with Refractory Inhibitors

Retrieved on: 
Tuesday, October 11, 2022
TCR, VIII, IND, ADA, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Biotechnology, Whole blood, Investigational New Drug, Food, Company, Doctor of Philosophy, Atopic dermatitis, Safety, A, GLOBE, ITI, Teff, FDA, Haemophilia A, Haemophilia, Pharmaceutical industry, Vaccine, Regulatory T cell

TI-168 is a next-generation, autologous FVIII TCR-Treg cell therapy candidate to eliminate FVIII inhibitors in HA patients.

Key Points: 
  • TI-168 is a next-generation, autologous FVIII TCR-Treg cell therapy candidate to eliminate FVIII inhibitors in HA patients.
  • The multi-center, open-label, Phase 1/2a study is designed to assess the safety and efficacy of TI-168 in up to eighteen congenital hemophilia A (HA) patients with refractory inhibitors.
  • All subjects will continue to receive mandatory prophylactic emicizumab and standard of care treatment with their usual episodic agents to treat breakthrough bleeds, as needed.
  • The primary objectives are to evaluate the safety and feasibility of TI-168 and determine the maximum tolerated dose.

Seraxis Announces Appointment of Chief Medical Officer, Dr. Paul Strumph

Retrieved on: 
Tuesday, August 30, 2022
JDRF, Survival, Research, Bristol Myers Squibb, Lexicon Pharmaceuticals, Type 1 diabetes, Endocrinology, GlaxoSmithKline, GLOBE, Liberal Mid-America Regional Airport, IQVIA, Biotechnology, Pharmaceutical industry

GERMANTOWN, Md., Aug. 30, 2022 (GLOBE NEWSWIRE) -- The regenerative medicine company Seraxis Inc. today announced the appointment of Paul Strumph, M.D.

Key Points: 
  • GERMANTOWN, Md., Aug. 30, 2022 (GLOBE NEWSWIRE) -- The regenerative medicine company Seraxis Inc. today announced the appointment of Paul Strumph, M.D.
  • Dr. Strumph is an endocrinology and diabetes care and research specialist with a successful career of bringing anti-diabetes treatments to market.
  • The depth of his expertise in clinical strategy and development will be pivotal as Seraxis transitions into a clinical-stage company," said William Rust, Ph.D., founder and Chief Executive Officer at Seraxis.
  • Previously, Dr. Strumph was Chief Medical Officer of Metavant Sciences, Vice President, Clinical Development at Lexicon Pharmaceuticals, North America Regional Chief Medical Officer at Quintiles and Chief Medical Officer of the Juvenile Diabetes Research Foundation (JDRF).

AM Best Revises Outlooks to Negative for Germantown Mutual Insurance Company

Retrieved on: 
Wednesday, August 3, 2022
Insurance, Professional Services, Credit, AM, Industry, Wind, News, Insurance, AM Best, ERM, Risk, ALL, Risk management

AM Best has revised the outlooks to negative from stable and affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating to a (Excellent) of Germantown Mutual Insurance Company (Germantown Mutual) (Germantown, WI).

Key Points: 
  • AM Best has revised the outlooks to negative from stable and affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating to a (Excellent) of Germantown Mutual Insurance Company (Germantown Mutual) (Germantown, WI).
  • The revised outlooks reflect Germantown Mutuals operating performance results, which in recent years has shown some deterioration.
  • Weather-related events continue to impact the Germantown Mutuals results and it likely will report a second-straight year with a combined ratio above break-even.
  • AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry.

McNeill Hotel Company Forms Joint Venture Investment Partnership with Prospect Ridge; Will Operate Under McNeill Investment Group (MIG) Corporate Umbrella

Retrieved on: 
Tuesday, July 19, 2022
Commercial Building & Real Estate, Construction & Property, Finance, REIT, Professional Services, Small Business, Lodging, Other Construction & Property, Travel, Other Professional Services, PRI, History, University, Social, Almanac, MIG, Investment, Philosophy, Owner-operator, Medical Center, Goal, Industry, Neuberger Berman, Growth, Prospect, Social Security Government Pension Offset, Partnership, ESG, McNeill, Trust, Financial services, Hotel, Tourism, Biophysical environment, Prospect Ridge Academy, Pension

McNeill Investment Group Executive Chairman Phillip H. McNeill, Jr. made the announcement.

Key Points: 
  • McNeill Investment Group Executive Chairman Phillip H. McNeill, Jr. made the announcement.
  • Property management assignments will continue to be organized under McNeill Hotel Company, with the Prospect Ridge joint venture and McNeill Hotel Company units of newly formed McNeill Investment Group (MIG).
  • This is a landmark day in the history of our company, said Phillip H. McNeill, Jr.
  • When Mark Ricketts and I began McNeill Hotel Company, one of our original goals was to create a company that would be attractive to institutional investors.